

A Thalamocorticostriatal Dopamine Network for Psychostimulant-Enhanced Human Cognitive Flexibility

Gregory R. Samanez-Larkin, Joshua W. Buckholz, Ronald L. Cowan, Neil D. Woodward, Rui Li, M. Sib Ansari, Catherine M. Arrington, Ronald M. Baldwin, Clarence E. Smith, Michael T. Treadwa, Robert M. Kessler, and David H. Zald

Background: Everyday life demands continuous flexibility in thought and behavior. We examined whether individual differences in dopamine function are related to variability in the effects of amphetamine on one aspect of flexibility: task switching.

Methods: Forty healthy human participants performed a task-switching paradigm following placebo and oral amphetamine administration. [¹⁸F]fallypride was used to measure D2/D3 baseline receptor availability and amphetamine-stimulated dopamine release.

Results: The majority of the participants showed amphetamine-induced benefits through reductions in switch costs. However, such benefits were variable. Individuals with higher baseline thalamic and cortical receptor availability and striatal dopamine release showed greater reductions in switch costs following amphetamine than individuals with lower levels. The relationship between dopamine receptors and stimulant-enhanced flexibility was partially mediated by striatal dopamine release.

Conclusions: These data indicate that the impact of the psychostimulant on cognitive flexibility is influenced by the status of dopamine within a thalamocorticostriatal network. Beyond demonstrating a link between this dopaminergic network and the enhancement in task switching, these neural measures accounted for unique variance in predicting the psychostimulant-induced cognitive enhancement. These results suggest that there may be measurable aspects of variability in the dopamine system that predispose certain individuals to benefit from and hence use psychostimulants for cognitive enhancement.

Key Words: Amphetamine, cognitive control, dopamine, flexibility, parietal cortex, PET, prefrontal cortex, striatum, thalamus

Cognitive flexibility refers to the broad set of skills used in everyday life to adjust behavior according to the changing demands of the environment. These skills have been associated with corticostriatal brain regions (1–8) modulated by the biogenic amines dopamine (DA), serotonin, and norepinephrine (9,10). The ability to switch tasks represents an important component of cognitive flexibility because it is essential for adaptively adjusting behavior in response to changing internal or external needs. This ability can be quantified as the additional amount of time it takes to switch to a new task relative to repeating the same task (“switch cost”) (11). Deficits in this ability arise in a number of neuropsychiatric disorders including

attention-deficit/hyperactivity disorder (12) and Parkinson’s disease (13), as well as in normal aging (14).

Task switching has both theoretically (15) and empirically been associated with the neuromodulator DA. Although manipulations of the DA system affect switch costs (12,13,16–18), responses to such manipulations are variable across participants. Understanding such variability is critical for evaluating the utility of agents aimed at modulating the DA system in a given individual. This issue takes on particular importance for psychostimulants given their widespread licit and illicit usage for promoting attention and alertness (19).

Genetic studies suggest that heritable individual variability in the function or expression of DA signaling pathway components, including catechol-*O*-methyltransferase, the DA transporter, and D2 receptors may contribute to individual differences in switch costs (20–23). However, to date these genetic studies have not directly measured DA functioning; thus, the relationship between variability in DA and individual differences in behavior are inferred rather than empirically observed. Indeed, knowledge of the cognitive correlates of individual differences in DA functioning of specific brain regions is largely absent from the human literature because cognitive genetic association studies are typically unable to provide information about regional specificity, and most DA positron emission tomography (PET) imaging studies use low-affinity radioligands (e.g., [¹¹C]raclopride) that are only suitable for assessing binding potential in the striatum.

In this study, we examined individual differences in psychostimulant enhancement of cognitive flexibility, specifically focusing on task switching (11), by combining pharmacologic manipulation of the DA system with PET imaging of DA D2/D3 receptors in healthy young adults. Given previous studies suggesting that the ability of DA agonists to enhance task-switching behavior may depend on interindividual variation in DA networks (20), we examined whether measures of receptor availability and

From the Department of Psychology (GRS-L, DHZ) and Institute of Imaging Science (GRS-L), Vanderbilt University, Nashville, Tennessee; Department of Psychology (JWB), Harvard University, Cambridge, Massachusetts; Departments of Psychiatry (RLC, NDW, DHZ) and Radiology and Radiological Sciences (RL, MSA, RMK), Vanderbilt University, Nashville, Tennessee; Department of Psychology (CMA), Lehigh University, Bethlehem, Pennsylvania; Molecular Neuroimaging (RMB), New Haven, Connecticut; DXP Imaging (CES), Norton Neuroscience Institute, Louisville, Kentucky; and Department of Psychiatry (MTT), McLean Hospital/Harvard Medical School, Belmont, Massachusetts.

Address correspondence to Gregory R. Samanez-Larkin, Ph.D., Psychological Sciences, Vanderbilt University, 111 21st Avenue South, Nashville, TN 37240-7817; E-mail: g.samanezlarkin@vanderbilt.edu.

Received Feb 15, 2012; revised and accepted Oct 31, 2012.

psychostimulant-induced DA release predict individual differences in the cognitive benefits of amphetamine (d-AMPH) administration.

Methods and Materials

Participants

Forty neurologically and psychiatrically healthy right-handed adult human participants (mean age = 22.4, range 18–33; 21 men, 19 women) with estimated IQ greater than 80 and no history of substance abuse were studied as part of an ongoing investigation of individual differences in striatal and extrastriatal DA release. All participants provided written informed consent approved by the Vanderbilt University Institutional Review Board. Female participants were studied during the early follicular phase of their menstrual cycle. Full screening and study eligibility details are provided in [Supplement 1](#).

Task Switching

All participants completed a classic task-switching paradigm (24) ([Figure S1 in Supplement 1](#)). The task included predictable switches on every other trial (see [Methods in Supplement 1](#) for more details). There were 352 trials per session. Switch costs were calculated as the difference between the average reaction time on switch trials (magnitude to odd–even; odd–even to magnitude) and the average reaction time on repetition trials (odd–even to odd–even; magnitude to magnitude) collapsing across two response-to-stimulus intervals (see [Results in Supplement 1](#) for details).

Participants completed one round of the switch task (352 trials) on placebo and a second round (352 trials) on a .43 mg/kg oral dose of d-AMPH. Participants performed the task approximately 90 minutes after ingesting the drug and before entering the PET scanner. This time delay was selected as the likely peak time for observing behavioral effects of the drug. We selected d-AMPH as the pharmacologic agent because of its widespread use (both licit and illicit) as a cognitive enhancer and its ability to stimulate DA release in a manner that reliably displaces our radiotracer, [¹⁸F]fallypride. It is this latter property that allows us to measure individual differences in DA responses to d-AMPH in both striatal and extrastriatal regions (25). The sessions were separated by an average of 18.5 days (*SD* = 19.8, range = 1–85). Number of days between sessions was uncorrelated with changes from placebo to d-AMPH for both mean reaction time, $r = .08$, $p = .61$, and switch cost, $r = .05$, $p = .77$. Basic speed of processing and motor measures were also collected during both the placebo and d-AMPH sessions and included digit symbol coding, symbol search, finger tapping, and toe tapping to ensure that observations were specific to task switching and did not reflect simple psychomotor processing speed. A subset of 10 of these participants completed two rounds of the task (separated by the same number of days as their original two sessions) several years later to estimate the effect of task repetition in the absence of a drug (see [Results in Supplement 1](#)). This follow-up was conducted 4–5 years after the tasks were completed the first time, so it is unlikely that any initial exposure to the task carried over across this interval. An additional, separate sample of 10 healthy young adults (aged 21–30) performed the task twice but did not receive d-AMPH or undergo PET imaging (see [Results in Supplement 1](#)).

PET Acquisition and Preprocessing

All PET images were acquired using [¹⁸F]fallypride. Unlike other D2/D3 ligands, [¹⁸F]fallypride allows stable estimates of D2/

D3 binding in both striatal and extrastriatal regions (26,27) with high test–retest reliability (see [Methods in Supplement 1](#) for more details). Protocols for PET image acquisition and analysis were derived from a larger ongoing study and have been previously published (26,28,29).

Participants received two PET scans using [¹⁸F]fallypride. The first scan was a baseline placebo scan; the second scan was performed while the participant received a d-AMPH challenge. PET imaging was performed on a GE Discovery LS scanner (GE, Milwaukee, Wisconsin) located at Vanderbilt University Medical Center that was upgraded to a Discovery STE system (GE) during the course of the study (10 participants on LS, 30 participants on STE). All participants received their baseline and d-AMPH scans on the same scanner. Prior analyses with the same data set reveal no significant differences between scanners (28). Nevertheless, scanner was included here as a covariate in all analyses. Following reconstruction both scanners had similar in-plane and through-plane resolution. [¹⁸F]fallypride was produced in the radiochemistry laboratory attached to the PET unit, following synthesis and quality control procedures described in U.S. Food and Drug Administration Investigational New Drug application (30). Scans were timed to start 3 hours after .43 mg/kg oral d-AMPH administration, which was timed to coincide with the period of peak plasma d-AMPH. 3-D emission acquisition scans were performed following a 5.0 mCi slow bolus injection of [¹⁸F]fallypride (specific activity >3,000 Ci/mmol). Serial scans were started simultaneously with the bolus injection of [¹⁸F]fallypride and were obtained for approximately 3.5 hours, with two 15-minute breaks for participant comfort. Computed tomography transmission scans were collected for attenuation correction before each of the three emission scans.

Each participant's serial PET scans were first corrected for motion across scanning periods and then coregistered to the participant's structural T1-weighted magnetic resonance (MR) image (see [Supplement 1](#) for MR imaging details). Regional D2/D3 binding potential, nondisplaceable (BP_{ND}) was calculated on a voxelwise basis using the full reference region method (31), with cerebellum chosen as the reference region because of its relative lack of D2/D3 receptors (32). Using the full reference region method, we have shown near-perfect correlation ($r = .99$) with modeled estimates using a metabolite-corrected plasma input function (33). Although this approach is slower computationally than the simplified (three-parameter) tissue reference method, it robustly estimates the key variable of interest (binding potential), and we have observed excellent convergence of modeled fits in regions with both high and low DA D2/D3 receptor levels. Voxelwise kinetic modeling was executed using Interactive Data Language. Individual voxelwise images of percent-change in [¹⁸F]fallypride binding from placebo to d-AMPH (representing percent-change in DA release) were created by subtracting each participant's d-AMPH scan from their placebo scan and dividing the resulting imaging by the placebo scan.

Individual Difference Analyses

Before the group analyses, a composite PET binding potential/T1-weighted MR image was created for each participant and warped to Montreal Neurological Institute space. The transformation matrix from this warping was then applied to the binding potential maps to bring all participants' data into a common space. Individual difference analyses of the PET data were performed in SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/>) by separately regressing participants' switch cost scores against their D2/D3 binding (placebo) and d-AMPH-induced DA release (percent-




Figure 1. The behavioral measure of inflexibility (switch cost) was reduced with an oral dose of amphetamine (d-AMPH) for most participants. Gray line is unity line (placebo switch cost = d-AMPH switch cost). $N = 40$.

change) images. In all cases, age, sex, and scanner were included as covariates. Statistical parametric maps were thresholded at a height of $t > 3$; cluster threshold was set to 30 contiguous voxels. Only voxels within clusters surviving a cluster extent correction for multiple comparisons ($p_{FDR} < .05$) at this threshold are reported. The topologic false discovery rate default in SPM8 was used here, but the results are unchanged if the correction is changed to family-wise error rate.

Structural Equation Modeling

A structural equation model was used to illustrate the relationships between DA binding potential and release across a thalamic, cortical, and striatal network and their influence on d-AMPH-induced cognitive flexibility. For the latent variable, one of three paths to the manifest variables was fixed to an unstandardized coefficient of 1 during model fitting.

Results

Behavioral Results

The majority of participants showed a behavioral benefit of d-AMPH. In addition to an overall decrease in mean reaction time under d-AMPH (744 msec, $SD = 157$) compared with placebo (837 msec, $SD = 196$), mean switch costs were also reduced under d-AMPH (210 msec, $SD = 101$) compared with placebo (299 msec, $SD = 115$). The average reduction in switch cost from placebo to d-AMPH (placebo - d-AMPH = 89 msec, $SD = 89$) was significant across the sample, $t(39) = 6.32$, $p < .0001$. For comparison of switch costs under placebo and d-AMPH, see Figure 1. Additionally, the magnitude of the d-AMPH increase in cognitive flexibility was predicted by baseline switch costs, $r = .53$, $p < .001$, such that individuals with larger switch costs under placebo showed greater behavior change.

Neuroimaging Results

The behavioral increase in flexibility (i.e., average reduction in switch cost from placebo to d-AMPH) was also associated with baseline DA D2/D3 receptor availability (as indexed by [18 F]fallypride binding potential, nondisplaceable: BP_{ND}) in the lateral prefrontal cortex, left thalamus, and right inferior parietal lobule ($p < .05$ whole-brain corrected). In each region, higher levels of BP_{ND} were associated with larger d-AMPH-associated cognitive benefits (see Figure 2; Table S1 in Supplement 1). Increases in flexibility were also associated with DA release in the striatum ($p < .05$ whole-brain corrected) as indexed by the change in [18 F]fallypride BP_{ND} following d-AMPH. Higher levels of DA release in anteromedial aspects of the caudate head were associated with larger cognitive benefits (Figure 3; Table S1 in Supplement 1). Although this cluster appears to extend into the white matter immediately anterior to the caudate, note that the spatial resolution of the PET data is much lower than the MR imaging template used as the underlay in the figures. No regions showed effects in




Figure 2. Increases in cognitive flexibility (reductions in switch cost) were associated with dopamine (DA) D2/D3 binding potential in the (A) lateral frontal cortex, (B) thalamus, and (C) parietal cortex. Scatterplot y axis is size of switch cost reduction from placebo to amphetamine in milliseconds (d-AMPH SC Δ). Scatterplot is displayed only as a sample depiction of effects to illustrate the absence of outliers. $N = 40$. BP_{ND} , binding potential, nondisplaceable; R, right.




Figure 3. Increases in cognitive flexibility (reductions in switch cost) were associated with dopamine (DA) release in the caudate. Scatterplot y axis is size of switch cost reduction from placebo to amphetamine in milliseconds (d-AMPH SC Δ). Scatterplot is displayed only as a sample depiction of effects to illustrate the absence of outliers. *N* = 40.

the opposite direction (i.e., negative correlation between BP_{ND} and cognitive benefit) at the whole-brain threshold. There were also no regions that were significantly associated with switch cost at baseline (placebo) at the cluster-corrected whole-brain threshold.

The associations between DA receptors and release in these regions and increased flexibility were specific and not simply a general cognitive or motor benefit. The relationships with baseline BP_{ND} and d-AMPH-induced release in these regions remained significantly associated with the d-AMPH behavioral benefit after controlling for performance on digit symbol coding, symbol search, finger tapping, or toe tapping tasks. The d-AMPH improvement in performance was significant for digit symbol coding, *t*(38) = 3.06, *p* < .005, and symbol search, *t*(39) = 8.20, *p* < .001, but nonsignificant for finger tapping, *t*(39) = 1.68, *p* = .10, and toe tapping, *t*(39) = 1.53, *p* = .13. Importantly, these basic measures of motor change post d-AMPH were not associated with changes in switch costs (all $|r| < .19$, *p* > .26). Follow-up analyses also revealed that motor change measures were not significantly associated with prefrontal cortical BP_{ND} (all $|r| < .29$, *p* > .08), parietal cortical BP_{ND} (all $|r| < .26$, *p* > .12), thalamic BP_{ND} (all $|r| < .26$, *p* > .13), or caudate DA release (all $|r| < .15$, *p* > .36). Follow-up quadratic (inverted-U) effects were tested with data extracted from regions of interest in the lateral prefrontal cortex, parietal cortex, thalamus, and caudate. These measures of DA receptors (cortex, thalamus) and release (caudate) for each regions of interest were average BP_{ND} values across each cluster identified in the whole-brain analyses examining individual

differences in the drug effect. All relationships were linear, with no evidence of an additional inverted-U relationship between the neural measures and behavior change in any of these regions.

Stepwise regression analyses examined whether the neural measures explained additional variance in predicting behavioral benefits of d-AMPH over baseline performance levels alone (Table 1). As reported earlier, in the first step placebo switch costs (i.e., baseline performance) explained a significant amount of variance in the d-AMPH behavioral benefit. For step two, a composite of thalamic-cortical BP_{ND} was created by averaging the z-scored measures of BP_{ND} across the thalamus, lateral frontal cortex, and parietal cortex (BP_{ND} measures in these three regions were highly correlated consistent with past analyses (26); all *r*s > .58, *p* < .0001). In step two, significantly more variance in behavior change was explained by the addition of thalamic-cortical BP_{ND} (*R*² change = .29), *F*(1,34) = 23.59, *p* < .0001. In step three, significantly more variance was explained by adding caudate DA release to the model from step two (*R*² change = .06), *F*(1,33) = 5.31, *p* < .05. Importantly, the behavioral measure of the drug benefit used in this regression model is based on a subtraction from the baseline behavioral measure. Thus, the evidence that the size of the d-AMPH-induced reduction in switch cost is partially explained by the baseline switch cost is not surprising. However, this analysis demonstrates that the subcortical and cortical PET measures explain variance above and beyond that provided by baseline behavioral performance alone. Note that we use the term “thalamic-cortical” to refer to this correlated network of thalamic and cortical regions where

Table 1. Behavioral and Neural Predictors of Amphetamine-Induced Cognitive Flexibility

	d-AMPH Switch Cost Reduction		
	Step 1	Step 2	Step 3
Placebo Switch Cost ^a	.52 (.14); 3.64 ^b	.30 (.12); 2.51 ^c	.26 (.12); 2.29 ^c
Thalamic-Cortical DA BP _{ND} ^a	—	.76 (.16); 4.86 ^b	.54 (.18); 3.10 ^d
Caudate DA Release ^a	—	—	.30 (.13); 2.30 ^c
Age ^a	-.07 (.15); -.49	.17 (.13); 1.31	.09 (.12); .74
Sex ^a	-.03 (.14); -.21	-.13 (.11); -1.12	-.11 (.11); -1.02
Scanner ^a	.05 (.15); .34	.25 (.12); 1.97	.21 (.12); 1.80
<i>R</i> ²	.29 ^c	.58 ^b	.64 ^b
Adjusted <i>R</i> ²	.21 ^c	.52 ^b	.57 ^b
Observations	40	40	40

BP_{ND}, binding potential, nondisplaceable; d-AMPH, amphetamine; DA, dopamine.

^aCoefficient (SEM); *t* statistic.

^b*p* < .001.

^c*p* < .05.

^d*p* < .01.




Figure 4. Structural equation model of the thalamocortical network effects on psychostimulant-enhanced cognitive flexibility. Path coefficients are standardized regression betas. The path between the thalamic-cortical latent variable and the thalamus manifest variable was fixed to an unstandardized coefficient of 1 during estimation. All paths are significant at $p < .05$. Lowercase encircled “e” indicates residual error variance terms. d-AMPH SC Δ = switch cost reduction from placebo to amphetamine (expressed as an increase in flexibility). BP_{ND}, binding potential, nondisplaceable.

receptor availability is associated with the effect of d-AMPH. We are not using the term to refer to the glutamatergic thalamo-cortical projections from thalamus to cortex.

In the full model (step three) thalamic-cortical BP_{ND} and caudate DA release were significant predictors of increased flexibility (Table 1), suggesting that they each contribute at least some unique variance. A structural equation model was used to formalize both the relationships between these regions and their unique effects on behavior change. A model in which thalamic-cortical BP_{ND} (represented as a single latent variable indexed by thalamic, frontal, and parietal BP_{ND}) and caudate DA release are significantly correlated but also uniquely predict psychostimulant-enhanced cognitive flexibility provided a good fit to the data ($\chi^2_4 = 4.69$, $p = .32$; confirmatory fit index = .99, root mean square error of approximation = .066). The model is displayed in Figure 4 with path coefficients. All paths in the model are significant at $p < .05$. Although both thalamic-cortical BP_{ND} and striatal DA release are significantly associated with behavior change, the model also demonstrates a partial mediation effect such that the influence of thalamic-cortical BP_{ND} on stimulant-enhanced flexibility is partially mediated by the impact of thalamic-cortical BP_{ND} on DA release in the striatum (Sobel test = 2.20, $p < .05$).

Discussion

This study indicates that the psychostimulant d-AMPH generally enhances task switching in healthy young adults, with improvements exceeding those that can be explained by simple motor effects alone. The overall enhancement in task switching is consistent with both theoretical accounts of a role for DA in allowing switching of behavioral outputs (15) and prior evidence that levodopa and methylphenidate reduce switch costs (12,13) in patient populations. However, to our knowledge, this is the first study to demonstrate the beneficial effect of d-AMPH on switch costs in healthy human participants. As expected, there were significant individual differences in the degree to which d-AMPH reduced switch costs. Critically, the extent to which participants showed improvement in cognitive flexibility following d-AMPH was associated with individual differences in a dopaminergic network of cortical and subcortical brain regions.

Improvements in performance from placebo to d-AMPH were predicted by D2/D3 receptor availability in the lateral frontal and parietal cortices and thalamus. The localization of these relationships in lateral frontal and parietal regions is consistent with lesion studies and functional and structural imaging literature on task switching (3–5,7,8,22). The evidence that individuals with a

greater number of available (unoccupied) D2/D3 receptors show larger benefits of d-AMPH for task switching suggests that having more sites for DA to act in the thalamus and cortex aids in its enhancement of cognitive function.

The effects of cortical D2 engagement may be understood within existing models of prefrontal DA action (34). According to this model, D1 and D2 receptors alter the response properties of prefrontal neurons, such that D1 receptors enhance the maintenance of information in working memory buffers by suppressing the ability of distracters to engage local circuitry, whereas D2 receptors lower the barriers for new or different information to gain access to these buffers, promoting flexibility. Updating has been shown to be linked more strongly to D2 receptor stimulation than D1 receptor stimulation (35,36). In the context of task switching, enhancing D2 signaling may improve task switching by facilitating the accessibility of new information to working memory, thus preventing unnecessarily long maintenance of the prior task rule.

It is likely that any enhanced signaling here is occurring within an optimal range because excessive D2 signaling will degrade attentional performance by promoting distractibility (36,37). It should also be noted that d-AMPH will have an impact on D1 receptors. The D2-sensitive ligand used in our study does not provide evidence about the relative D1 and D2 dominance in the cortex. Although there is strong pharmacologic and genetic evidence for a selective relationship between D2 receptor function and flexibility (20), we did not measure D1 receptors here, and, at present, data linking PET measures to these specific state conditions is lacking.

Critically, a positive relationship was also found between DA release in the caudate and the psychostimulant enhancement of task switching. It has been suggested that striatal DA may play a more central role than cortical DA in flexibility (38). Striatal DA has been shown to influence the neural efficiency of other dorsolateral striatal and prefrontal cortical regions, which directly influence switching behavior. Striatal DA may also serve a gating function on cortical connections (39,40), which may aid in the continuous alternation of responses required by the task.

Although we found specific associations between DA receptors and release and the cognitive benefit of d-AMPH, it is important to acknowledge that the effects of these stimulants are not limited to the DA system. d-AMPH and methylphenidate also act on the norepinephrine transporter. Thus, this behavioral benefit is also likely to be partially dependent on other neurochemical systems (10,41). Nevertheless, a significant portion of the variance in behavior change was accounted for by individual

differences in DA binding potential and release (adjusted R^2 range was .20–.38 across individual regions). We did not assess other neurochemical systems here, so it is not possible to examine potential relationships between behavior change and variability in the norepinephrine system or directly compare the size of the effects between neuromodulators.

Although previous studies have examined relationships between DA drug effects on other flexibility measures (e.g., reversal learning) and striatal DA function (42,43), the goal of the whole-brain approach in this study was to better characterize the role of a broader DA network. A structural equation model was used to test the hypothesized associations between these cortical and subcortical effects and their relationship with psychostimulant-enhanced flexibility. The model supports the hypothesis that these regions compose a unified network but also make independent contributions to behavior change. The set of regions in this network is remarkably consistent with documented thalamocortico-striatal circuits (44,45). Although thalamic activation has been reported in studies of task switching (1,2,8), it is rarely discussed. The results of our study support an important role for the thalamus in this dopaminergic network (44,46–48). In previous discussions of the role of cortico-striatal circuits in switching, there is an implicit assumption that the loops proceed through thalamic relays. However, the observation that D2/D3 binding potential in the thalamus influences the results suggests that there could be a more explicit influence of the thalamus that extends beyond an automatic relay. As such, we adopt the term “thalamocortico-striatal” in describing this network. Of course, a complete circuit model of these thalamic, cortical, and striatal regions necessarily includes gamma-aminobutyric acid-ergic and glutamatergic pathways that we did not measure here. Our use of the “network” terminology refers to the correlated DA receptor and release effects in thalamic, cortical, and striatal regions.

The results also demonstrate a partial mediation effect such that the thalamic and cortical receptor influence on stimulant-enhanced flexibility is partially mediated by striatal DA release. The relationship between thalamic and cortical binding potential and striatal DA release is specified directionally for two reasons. First, the measure of DA release that we use in this study is d-AMPH induced and depends on baseline levels of DA receptors. Second, directionality is anatomically predicted by well-known dorsolateral prefrontal loops that include direct pathways from the prefrontal cortex to the striatum. Although we model directionality, more generally, it is possible that this relationship could be bidirectional. Although previous studies and theory have emphasized the opponent roles of the striatum and prefrontal cortex for supporting flexibility and stability, respectively (36), our results suggest that both striatal and cortical regions may be serving complementary functions.

Some limitations in the study should be noted. The order of administration of placebo and drug was not counterbalanced. Although two sets of additional behavioral data suggest that the drug effects are larger than the task repetition effects (Results in Supplement 1), we cannot completely rule out the possibility that a portion of the variance in performance across participants may also be related to individual differences in learning ability (42,43). Future studies will need to collect measures of both flexibility and learning to formally examine these potential relationships. Also, the present sample was composed entirely of healthy young adults. It is not clear whether the same relationships would be observed in a clinical sample (49,50). Another important limitation is that the behavioral change was only examined

over a short time scale from a single dose of d-AMPH. We did not measure repeated exposure to the stimulant. It is possible that the flexibility benefits may plateau over time or even reverse with sensitization (51). A related limitation of using a single dose of d-AMPH in this study is that we cannot establish dose–response curves with the available data.

An increasing number of otherwise healthy adults use psychostimulants for cognitive enhancement (19). Despite the potential for addiction (52), individuals will continue to use d-AMPH and other psychostimulants to manipulate their attention and arousal (53,54). Our results suggest that there may be measurable aspects of variability in the DA system that predispose certain individuals to benefit from and hence use psychostimulants for cognitive enhancement. These factors may also influence the risk for abusing such medications. In a recent study, we found that increased DA release in the striatum was associated with increased self-reported desire for more d-AMPH (28). Although we did not specifically measure the perceived cognitive benefits here, it is possible that such perceived cognitive effects of initial stimulant exposure may be an important part of the subjective experience that contributes to the later development of addiction (55).

GRS-L was supported by National Institute of Mental Health Training Grant No. T32-MH018921, a National Institute on Aging postdoctoral fellowship (National Research Service Award F32-AG039131), and a National Institute on Aging Pathway to Independence Award (Grant No. K99-AG042596) during data analysis and manuscript preparation. This research was funded by National Institute on Drug Abuse (Grant No. R01-DA019670) to DHZ and was supported by Clinical and Translational Science Award Grant No. UL1TR000445 from the National Center for Advancing Translational Science. The contents of this article are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Science or National Institutes of Health.

Thanks to Evan Shelby and Ashley Schwartzman for assistance with data collection and to Chrystyna Kouros and Lauren Atlas for advice on structural equation modeling.

All authors report no biomedical financial interest or potential conflicts of interest.

Supplementary material cited in this article is available online.

1. Kimberg DY, Aguirre GK, D'Esposito M (2000): Modulation of task-related neural activity in task-switching: An fMRI study. *Brain Res Cogn Brain Res* 10:189–196.
2. Sohn MH, Ursu S, Anderson JR, Stenger VA, Carter CS (2000): The role of prefrontal cortex and posterior parietal cortex in task switching. *PNAS* 97:13448–13453.
3. Aron AR, Monsell S, Sahakian BJ, Robbins TW (2004): A componential analysis of task-switching deficits associated with lesions of left and right frontal cortex. *Brain* 127:1561–1573.
4. Cools R, Ivry RB, D'Esposito M (2006): The human striatum is necessary for responding to changes in stimulus relevance. *J Cogn Neurosci* 18:1973–1983.
5. Badre D, Wagner AD (2006): Computational and neurobiological mechanisms underlying cognitive flexibility. *PNAS* 103:7186–7191.
6. Esterman M, Chiu Y-C, Tamber-Rosenau BJ, Yantis S (2009): Decoding cognitive control in human parietal cortex. *PNAS* 106:17974–17979.
7. Gold BT, Powell DK, Xuan L, Jicha GA, Smith CD (2010): Age-related slowing of task switching is associated with decreased integrity of frontoparietal white matter. *Neurobiol Aging* 31:512–522.
8. Kim C, Johnson NF, Cilles SE, Gold BT (2011): Common and distinct mechanisms of cognitive flexibility in prefrontal cortex. *J Neurosci* 31:4771–4779.

9. Robbins TW (2007): Shifting and stopping: Fronto-striatal substrates, neurochemical modulation and clinical implications. *Philos Trans R Soc Lond B Biol Sci* 362:917–932.
10. Kehagia AA, Murray GK, Robbins TW (2010): Learning and cognitive flexibility: Fronto-striatal function and monoaminergic modulation. *Curr Opin Neurobiol* 20:199–204.
11. Monsell S (2003): Task switching. *Trends Cogn Sci* 7:134–140.
12. Kramer AF, Cepeda NJ, Cepeda ML (2001): Methylphenidate effects on task-switching performance in attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 40:1277–1284.
13. Cools R, Barker RA, Sahakian BJ, Robbins TW (2003): L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. *Neuropsychologia* 41:1431–1441.
14. Waslyshyn C, Verhaeghen P, Sliwinski MJ (2011): Aging and task switching: A meta-analysis. *Psychol Aging* 26:15–20.
15. Oades RD (1985): The role of noradrenaline in tuning and dopamine in switching between signals in the CNS. *Neurosci Biobehav Rev* 9: 261–282.
16. Evenden JL, Robbins TW (1985): The effects of d-amphetamine, chloridiazepoxide and alpha-flupenthixol on food-reinforced tracking of a visual stimulus by rats. *Psychopharmacology* 85:361–366.
17. Crofts HS, Dalley JW, Collins P, Van Denderen JC, Everitt BJ, Robbins TW, *et al.* (2001): Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. *Cereb Cortex* 11:1015–1026.
18. Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW (2004): Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. *Psychopharmacology* 176:331–342.
19. McCabe SE, Knight JR, Teter CJ, Wechsler H (2005): Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. *Addiction* 100:96–106.
20. van Holstein M, Aarts E, van der Schaaf ME, Geurts DEM, Verkes RJ, Franke B, *et al.* (2011): Human cognitive flexibility depends on dopamine D2 receptor signaling. *Psychopharmacology* 218:567–578.
21. Colzato LS, Waszak F, Nieuwenhuis S, Posthuma D, Hommel B (2010): The flexible mind is associated with the catechol-O-methyltransferase (COMT) Val158Met polymorphism: Evidence for a role of dopamine in the control of task-switching. *Neuropsychologia* 48:2764–2768.
22. Stelzel C, Basten U, Montag C, Reuter M, Fiebach CJ (2010): Fronto-striatal involvement in task switching depends on genetic differences in d2 receptor density. *J Neurosci* 30:14205–14212.
23. Aarts E, Roelofs A, Franke B, Rijpkema M, Fernández G, Helmich RC, *et al.* (2010): Striatal dopamine mediates the interface between motivational and cognitive control in humans: Evidence from genetic imaging. *Neuropsychopharmacology* 35:1943–1951.
24. Rogers R, Monsell S (1995): Costs of a predictable switch between simple cognitive tasks. *J Exp Psychol Gen* 124:207–231.
25. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, *et al.* (2006): Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. *Neuropsychopharmacology* 31: 1016–1026.
26. Zald DH, Woodward ND, Cowan RL, Riccardi P, Ansari MS, Baldwin RM, *et al.* (2010): The interrelationship of dopamine D2-like receptor availability in striatal and extrastriatal brain regions in healthy humans: A principal component analysis of [18F]fallypride binding. *Neuroimage* 51:53–62.
27. Christian BT, Narayanan T, Shi B, Morris ED, Mantil J, Mukherjee J (2004): Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. *J Cereb Blood Flow Metab* 24:309–322.
28. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS, *et al.* (2010): Dopaminergic network differences in human impulsivity. *Science* 329:532.
29. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Benning SD, Li R, *et al.* (2010): Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. *Nat Neurosci* 13:419–421.
30. Kessler RM (1995): Imaging of Cerebral Dopamine D2 Receptors; IND application 47,245.
31. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, *et al.* (1996): Comparison of methods for analysis of clinical [11C]raclopride studies. *J Cereb Blood Flow Metab* 16:42–52.
32. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994): Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. *Neuropsychopharmacology* 11: 245–256.
33. Kessler RM, Mason NS, Jones C, Ansari MS, Manning RF, Price RR (2002): [¹⁸F]N-allyl-5-fluoropropylpeptide (fallypride): Radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. *Neuroimage* 11:532.
34. Seamans JK, Yang CR (2004): The principal features and mechanisms of dopamine modulation in the prefrontal cortex. *Prog Neurobiol* 74: 1–58.
35. Wang M, Vijayraghavan S, Goldman-Rakic PS (2004): Selective D2 receptor actions on the functional circuitry of working memory. *Science* 303:853–856.
36. Cools R, D'Esposito M (2011): Inverted-U-shaped dopamine actions on human working memory and cognitive control. *Biol Psychiatry* 69: e113–e125.
37. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, *et al.* (2003): Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. *PNAS* 100: 6186–6191.
38. Cools R (2011): Dopaminergic control of the striatum for high-level cognition. *Curr Opin Neurobiol* 21:402–407.
39. van Schouwenburg MR, Ouden den HEM, Cools R (2010): The human basal ganglia modulate frontal-posterior connectivity during attention shifting. *J Neurosci* 30:9910–9918.
40. McNab F, Klingberg T (2008): Prefrontal cortex and basal ganglia control access to working memory. *Nat Neurosci* 11:103–107.
41. Berridge CW, Stalnaker TA (2002): Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. *Synapse* 46:140–149.
42. Clatworthy PL, Lewis SJG, Brichard L, Hong YT, Izquierdo D, Clark L, *et al.* (2009): Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. *J Neurosci* 29:4690–4696.
43. Cools R, Frank MJ, Gibbs SE, Miyakawa A, Jagust WJ, D'Esposito M (2009): Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. *J Neurosci* 29: 1538–1543.
44. Haber SN (2003): The primate basal ganglia: Parallel and integrative networks. *J Chem Neuroanat* 26:317–330.
45. Alexander GE, Crutcher MD, DeLong MR (1990): Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. *Prog Brain Res* 85:119–146.
46. Mink JW (1996): The basal ganglia: Focused selection and inhibition of competing motor programs. *Prog Neurobiol* 50:381–425.
47. Sánchez-González MA, García-Cabezas MA, Rico B, Cavada C (2005): The primate thalamus is a key target for brain dopamine. *J Neurosci* 25:6076–6083.
48. García-Cabezas MA, Martínez-Sánchez P, Sánchez-González MA, Garzón M, Cavada C (2009): Dopamine innervation in the thalamus: Monkey versus rat. *Cereb Cortex* 19:424–434.
49. Advokat C (2010): What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). *Neurosci Biobehav Rev* 34:1256–1266.
50. Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E (2005): Predicting stimulant medication response in ADHD: Evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. *J Integr Neurosci* 4:107–121.
51. Featherstone RE, Rizos Z, Kapur S, Fletcher PJ (2008): A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. *Behav Brain Res* 189: 170–179.
52. Swanson JM, Volkow ND (2008): Increasing use of stimulants warns of potential abuse. *Nature* 453:586.
53. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, *et al.* (2008): Towards responsible use of cognitive-enhancing drugs by the healthy. *Nature* 456:702–705.
54. Maher B (2008): Poll results: Look who's doping. *Nature* 452:647–675.
55. Lambert NM, McLeod M, Schenk S (2006): Subjective responses to initial experience with cocaine: An exploration of the incentive-sensitization theory of drug abuse. *Addiction* 101:713–725.